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osting by EAbstract Purpose: To detect if intravitreal bevacizumab can reduce retinal exudation, improve
visual and anatomical outcomes, and facilitate the treatment in various pediatric exudative retinal
diseases.
Patients and methods: Prospective, non-randomized, case series of nine eyes of pediatric exudative
retinal diseases less than 18 years old which included six eyes with juvenile diabetic retinopathy, two
eyes in children with Coats’ disease, and one eye with myopic choroidal neovascular membrane
(CNV). All eyes received only intravitreal bevacizumab injection 1.25 mg/0.05 ml as the primary
treatment. The need for adjuvant ablative procedures, including laser photocoagulation or cryo-
therapy, were performed and recorded. The need for supplementary intravitreal bevacizumab injec-
tion was recorded. The changes in pre- and post-operative best-corrected visual acuity (BCVA) and
central macular thickness (CMT) were recorded. Serial optical coherent tomography (OCT) and
fundus ﬂourescein angiography (FFA) were performed to follow treatment efﬁcacy.
Results: The study included 19 eyes of 11 patients with age equal to or less than eighteen years with
exudative retinal diseases including type I DM (n= sixteen eyes), Coats’ disease (n= 2 eyes), and
due to myopic CNV (n= 1 eye). Mean pre-injection log MAR for all was 0.605 ± 0.174 and mean
post-injection for all log MAR was 0.284 ± 0.247. While Mean pre-injection log MAR for DR and
myopic CNV patients was 0.576 + 0.152 SD and mean post-injection log MAR for DR and myopic
CNV patients was 0.229 + 0.189 at one year. Serial OCT measurements showed that mean CMT
for all eyes was 355.8 ± 35.3 lm SD at baseline, which was decreased to 222.42 + 26.2 lm SD. The551228104.
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194 A.G. Salmantwo eyes of Coats’ disease needed another two supplementary intravitreal bevacizumab injections.
No ocular or systemic complications related to bevacizumab were noted during the entire course of
follow-up.
Conclusion: Intravitreal bevacizumab appears to be a well-tolerated treatment for pediatric age
group with various exudative retinal diseases. It has the potential as an adjuvant therapy for abla-
tive procedures to improve ﬁnal visual and anatomical outcome.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Many causes of pediatric exudative retinal exudation are
known including juvenile diabetes (Murphy et al., 1990;
O¨zkirs, 2009), Coats’ disease (Shields and Shields, 2002), myo-
pic choroidal neovascular membrane (Sundaram, 2007). Dia-
betic retinopathy (DR) in children is not rare and that
postpubescent children have a greater prevalence of DR than
do prepubescent children with similar diabetes duration (Mur-
phy et al., 1990).
The current treatment modalities aim at obliterating the af-
fected retinal vessels by laser photocoagulation and cryother-
apy (Murphy et al., 1990; O¨zkirs, 2009; Shields and Shields,
2002).
Bevacizumab is a humanized monoclonal antibody that
competitively inhibits all isoforms of the VEGF-A family in
the extracellular space. While bevacizumab is currently ap-
proved by the Food and Drug Administration (FDA) for the
treatment of metastatic colorectal cancer, metastatic breast
cancer, and non-small cell lung cancer, it is widely used as
an off-label treatment for neovascular age-related macular
degeneration and retinal vascular disorders including retinal
vein occlusion and diabetic macular edema (O¨zkirs, 2009). Re-
cently it is also introduced in the management of pediatric ret-
inal diseases as in ROP (Kusaka et al., 2008) and Coats disease
(Shields and Shields, 2002).
Avastin was probably used for macular edema in diabetics,
for the occlusion of telangiectatic vessels in Coats, and for the
regression choroidal neovascularization in myopic children
(Shields and Shields, 2002).
However the use of intravitreal bevacizumab in pediatric
age group is still under research and its efﬁcacy and safety as
regards local and systemic adverse effects are still not clear.
Our study tried to evaluate the safety and efﬁcacy of intra-
vitreal bevacizumab in treatment of retinal exudation and its
value to improve visual and anatomical outcomes and facilitate
the treatment in various pediatric exudative retinal diseases.2. Patients and methods
The study, prospective, non-randomized, case series of nine
eyes of pediatric exudative retinal diseases less than eighteen
years old, was approved by the medical and ethics committee.
Inclusion Criteria were signed informed consent from the
parents with retinal exudation in age equal to or less than eigh-
teen years old and this exudation is threatening or involves the
macula with central macular thickness (CMT) more than
300 lm in the central subﬁeld as measured by Optical coher-
ence tomography (OCT) (Stratus OCT; Zeiss-Humphrey, Du-
bin, CA) and patients without a necessity for panretinal laser
photocoagulation for at least 3 months after study inclusion.Exclusion criteria were refusal of parents, unstable medi-
cal status including glycemic control and blood pressure, his-
tory of systemic corticosteroids within 3 months or previous
intravitreal injection, laser photocoagulation or other
ocular disorders as retinal vein occlusion or vitreomacular
traction.
For all patients full history taking from the parents plus
full ophthalmological evaluation of the child was done
including slit lamp biomicroscopy, indirect ophthalmoscopy
intraocular pressure measurement, gonioscopy, B scan ultra-
sonography, OCT, fundus ﬂourescein angiography (FFA),
fundus photography and systemic examination for any associ-
ated signs or complications, systemic investigation including
fasting, post-prandial blood sugar, HB A1C, liver and renal
function. This has to reach for the ﬁnal diagnosis for the rea-
son for the retinal exudation and to diagnose and document
the extent and severity of the disease before the start of intra-
vitreal injection.
All eyes received only intravitreal bevacizumab injection
1.25 mg/0.05 ml as the primary treatment. The changes in
pre- and post-operative best-corrected visual acuity (BCVA)
and CMT were recorded. Serial OCT and FFA were per-
formed to follow treatment efﬁcacy. According to the presence
or absence of the improvement after the injection in BCVA,
CMT, and FFA the need for supplementary intravitreal bev-
acizumab injection was decided, given and recorded or the
need for further therapy as laser photocoagulation.
Intravitreal injection of 1.25 mg/0.05 ml bevacizumab
(Avastin, Genentech, South San Francisco, CA, USA) was
given after full asepsis in the operation room. It was injected
into the vitreous cavity through the superotemporal quadrant,
4 mm from the limbus using 30-gauge needles with post-injec-
tion check of intraocular pressure. The patient was reviewed
on the ﬁrst post-injection days and at 1, 3, and 6 weeks after
each intervention and followed up to 12 months after the last
injection.
During follow-up we assessed the following criteria for each
patient:
(1) Initial and ﬁnal type and size of the exudation on FFA;
(2) Initial, ﬁnal, and BCVA during follow-up;
(3) Initial and ﬁnal CMT (OCT);
(4) Fundus photography;
(5) Follow-up time.
SPSS 17 was used for statistical analysis with the use of stu-
dent t -test (paired sample test) for the comparison of two
groups and (p 6 0.05) was considered as statistically signiﬁ-
cant, (p< 0.001) was considered as statistically highly signiﬁ-
cant, and (p> 0.05) was considered as statistically
insigniﬁcant.
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The study included 19 eyes of 11 patients with age equal to or
less than 18 years with exudative retinal diseases 6 males and 5
females including type I DM (n= 16 eyes), Coats’ disease
(n= 2 eyes) and due to myopic CNV (n= 1 eye) (Table 1).
Mean pre-injection log MAR for all was 0.605 ± 0.174 and
mean post-injection log MAR for all eyes at one year was
0.284 ± 0.247. While Mean pre-injection log MAR for DR
and myopic CNV patients was 0.576 + 0.152 SD and mean
post-injection log MAR for DR and myopic CNV patients
was 0.229 + 0.189 SD which was statistically highly signiﬁcant
(p< 0.001) (p= 0.000) while it was not signiﬁcantly improved
in Coats’ disease (p> 0.05).
Serial OCT measurements showed that mean CMT for all
eyes was 355.8 lm± 35.3 lm SD at baseline, which was de-
creased to 222.42 + 26.2 lm SD at last visit statistically highly
signiﬁcant (p< 0.001) (p= 0.000).
The two eyes of Coats’ disease needed another two supple-
mentary intravitreal bevacizumab injections after one month
interval between each injection.
For those two cases of Coats’ disease after we got the
beneﬁts from intravitreal bevacizumab injection of decreasedTable 1 Various data for pre- and post-injection of bevacizumab.
Eye no. Age
(years)
Sex Diagnosis Eye Mean pre-inj
CMT (lm)
M
C
1 18 Female DR OD 340 2
2 18 Female DR OS 330 2
3 17 Female DR OD 359 2
4 17 Female DR OS 351 2
5 17.5 Male DR OD 313 1
6 17.5 Male DR OS 333 2
7 18 Male DR OD 360 2
8 18 Male DR OS 370 2
9 17 Male DR OD 341 2
10 17 Male DR OS 363 2
11 17.5 Female DR OD 350 2
12 17.5 Female DR OS 458 2
13 18 Female DR OD 361 2
14 18 Female DR OS 375 2
15 17.5 Female DR OD 308 1
16 17.5 Female DR OS 314 1
17 7 Male Coats’ OD 400 2
18 8 Male Coats’ OD 395 2
19 17 Male Myopic CNV OS 340 2
Figure 1 OCT in DR patient left pre-injection CMOexudation, improvement of the hazy media with decrease of
the retinal thickness and edema we added for the treatment
laser photocoagulation after three months from the last
injection and improvement happened in the FFA leakage
but without further signiﬁcant improvement of the ﬁnal
BCVA.
The sixteen diabetic eyes were in stage of mild to moderate
non-proliferative diabetic retinopathy with clinically signiﬁ-
cant macular edema (in FFA twelve eyes were diffuse cystoid
macular edema and six eyes were with focal macular edema
but no case was with ischemic maculopathy) (Fig. 1).
The two eyes of Coats’ disease were stage II with FFA
peripheral vascularization, leakage with mild macular involve-
ment (Fig. 2).
The eye of myopic CNVM was minus 20 diopters error of
refraction, anisometropia and in FFA it was juxtafoveal in po-
sition, and diameter size was 150 lm (Fig. 3)
At 12 months follow-up, absence of ﬂuorescein leakage, mi-
cro aneurysms, and exudates were demonstrated in eighteen
eyes (94.7%) out of nineteen treated eyes and persistent leak-
age in one eye (5.3%) with Coats’ disease. No ocular or sys-
temic complications related to bevacizumab were noted
during the entire course of follow-up.ean post-inj
MT (lm)
Pre-inj
BCVA
Log MAR Post-inj
BCVA 1 year
Log
MAR
No.
of inj
19 20/100 0.7 20/40 0.3 1
11 20/100 0.7 20/60 0.5 1
29 20/100 0.7 20/60 0.5 2
21 20/80 0.6 20/40 0.3 2
90 20/60 0.5 20/20 0 1
10 20/60 0.5 20/20 0 1
05 20/100 0.7 20/40 0.3 1
15 20/100 0.7 20/40 0.3 1
19 20/80 0.6 20/40 0.3 1
41 20/100 0.7 20/40 0.3 1
30 20/80 0.6 20/40 0.3 1
38 20/100 0.7 20/40 0.3 1
22 20/40 0.3 20/20 0 2
36 20/60 0.5 20/20 0 2
81 20/40 0.3 20/20 0 1
89 20/40 0.3 20/20 0 1
90 20/200 1.0 20/160 0.9 3
70 20/100 0.7 20/80 0.6 3
10 20/100 0.7 20/60 0.5 1
in OCT and right 6 months post-injection OCT.
Figure 2 (Top) pre-injection (OCT and FFA) and (bottom) post-injection 6 months (OCT decrease edema and FFA decreased leakage).
Figure 3 (Top) Myopic CNVM pre-injection (left colored fundus, middle FFA and right OCT) and (bottom) post-injection 6 months
(left FFA and right OCT) membrane regressed.
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VEGF is a naturally occurring protein, which causes increased
vascular permeability (important for the initiation of angio-
genesis), endothelial cell migration, and proliferation (Sun
et al., 2007). Clinicians should also bear in mind the role of
VEGF in the development of retinal vessels not only in the ret-
inal periphery but also in the macula. Long-term visual out-
comes of the use of anti-VEGF agents in children are
unknown. In Coats’ disease, it is possible that with anti-VEGF
therapy, repeated injections may be needed (Sun et al., 2007).Anti-VEGF being an adjunct treatment, the timing of this
may be varied depending on the clinical judgment. In cases
with extensive exudation and media haze, laser may be de-
ferred while anti-VEGF agents may be the preferred treatment.
Due to their anti-permeability role, they may be utilized to
clear the exudation and media haze to visualize the vessels
for ablation. Also, in cases with previous unsuccessful laser
treatment for macular edema, anti-VEGF agents may be the
preferred treatment.
Sun et al. (2007) showed elevated levels of VEGF in Coats’
disease which rapidly reduced after injection of pegaptanib
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(normal – 100 pg/ml) and an improvement of exudation, hem-
orrhage, and near complete reattachment of the retina. Thus,
they suggested that there may be a component of dysregulation
of VEGF-mediated angiogenesis in Coats’ disease (Sun et al.,
2007).
We used intravitreal bevacizumab 1.25 mg/0.05 ml as a pri-
mary treatment for pediatric retinal exudation and this was
used in nineteen eyes (sixteen eyes NPDR,2 Coats’ disease
and one myopic CNVM). Mean pre-injection log MAR for
all was 0.605 ± 0.174 and mean post-injection log MAR for
all eyes at one year was 0.284 ± 0.247. While Mean pre-injec-
tion log MAR for DR and myopic CNV patients was
0.576 + 0.152 SD and mean post-injection log MAR for DR
and myopic CNV patients was 0.229 + 0.189 SD which was
statistically highly signiﬁcant (p< 0.001) (p= 0.000) while it
was not signiﬁcantly improved in Coats’ disease (p> 0.05).
Serial OCT measurements showed that mean CMT for all
eyes was 355.8 ± 35.3 lm SD at baseline, which was decreased
to 222.42 + 26.2 lm SD at last visit statistically highly signif-
icant (p< 0.001).
So anatomical improvement was present in all cases of ret-
inal exudation in pediatric age group injected with intravitre-
al bevacizumab and this was in agreement with other studies
done in adult diabetic retinal exudation and macular edema
(O¨zkirs, 2009; Haritoglou et al., 2006), in myopic CNVM
(Sundaram, 2007), and in Coats’ disease (Venkatesh et al.,
2008). While functional improvement was present only in ret-
inal exudation in DR and myopic CNV in pediatric age
group.
In our study we needed single injection of bevacizumab in
12 eyes (63%) of cases in pediatric retinal exudation and three
injections were only needed in Coats’ disease due its chronicity
and this was in agreement with Venkatesh et al. (2008).
In our study Coats’ disease improved anatomically with
intravitreal bevacizumab treatment despite a lack of improve-
ment in vision and this may be due to the chronicity of the
macular edema that once lipid plaques have deposited on the
macula; it is usually irreversible and often leads to permanent
visual loss and this was in disagreement with Morteza et al.
(2010) who showed dramatic improvement of both anatomical
and visual outcome of Coats’ disease after intravitreal bev-
acizumab injection (Entezari et al., 2010). Intravitreal bev-
acizumab effectively decreases vascular permeability and
retinal edema in the short term.
No ocular or systemic complications related to bev-
acizumab were noted during the entire course of follow-up.5. Conclusion
Intravitreal bevacizumab appears to be a well-tolerated treat-
ment for pediatric age group with various exudative retinal dis-
eases even with multiple injections but it is less effective in
Coats’ disease. It has the potential as a single or an adjuvant
therapy for ablative procedures to improve ﬁnal visual and
anatomical outcome. However, further prospective, random-
ized, controlled clinical trials with larger number of enrolled
patients are necessary to determine the best choice of drug,
as well as optimal dose and timing, the need for repeat treat-
ments, and the possibility of ocular or systemic complications
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